SEARCH

SEARCH BY CITATION

References

  • 1
    Huria A, Somlo G, Ahles T. Renaming “chemobrain.” Cancer Invest. 2007; 25: 373-377.
  • 2
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995; 4: 61-66.
  • 3
    Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90: 210-218.
  • 4
    Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640-650.
  • 5
    Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18: 2695-2701.
  • 6
    Kreukals BP, Van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008; 8: 80-87.
  • 7
    Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003; 3: 215-222.
  • 8
    Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004; 26: 955-969.
  • 9
    Mehnert A, Scherwath A, Schirmer L, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns. 2007; 66: 108-118.
  • 10
    Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008; 26: 768-777.
  • 11
    Janz NK, Mujahid M, Chung LK, et al. Symptom experience and quality of life of women following breast cancer treatment. J Womens Health (Larchmt). 2007; 16: 1348-1361.
  • 12
    Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008; 26: 971-982.
  • 13
    Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer. 2008; 16: 577-583.
  • 14
    Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions [review]. Palliat Support Care. 2007; 5: 273-280.
  • 15
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence of narcolepsy. Ann Neurol. 1998; 43: 88-97.
  • 16
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000; 54: 1166-1175.
  • 17
    Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997; 49: 444-451.
  • 18
    Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 2000; 1: 109-116.
  • 19
    Czeisler CA, Walsh JK, Roth T, et al,US Modafinil in Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005; 353: 476-486.
  • 20
    Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000; 14: 53-60.
  • 21
    Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005; 30: 100-107.
  • 22
    Morrow GR, Ryan JL, Kohli S, et al. Supportive care in cancer [abstract]. 2006;583-687. Abstract 11-070.
  • 23
    Yoshitake H. Three characteristic patterns of subjective fatigue symptoms. Ergonomics. 1978; 21: 231-233.
  • 24
    McNair DM, Lorr M, Droppelman LF. Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service; 1971.
  • 25
    Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85: 1186-1196.
  • 26
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46: 1121-1123.
  • 27
    Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89: 1634-1646.
  • 28
    Booth-Jones M, Jacobsen PB, Ransom S, Soety E. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005; 36: 695-702.
  • 29
    Baranski JV, Pigeau RA. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res. 1997; 6: 84-91.
  • 30
    Caldwell JA, Caldwell JL, Smythe NK, Hall KK. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology (Berl). 2000; 150: 272-282.
  • 31
    Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl). 2002; 159: 238-247.
  • 32
    WinninghamML, GroenwaldSL, GoodmanM, FroggeMH, YarboCH, eds. Cancer Symptom Management. Boston, MA: Jones and Barlett; 1996: 42-54.
  • 33
    Simpson P, Wesnes K, Christmas L. A computerized system for the assessment of drug-induced performance changes in young, elderly or demented populations. Br J Clin Pharmacol. 1987; 27: 711P-712P.
  • 34
    Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a ginkgo biloba/panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000; 152: 353-361.
  • 35
    Wesnes KA, Simmons D, Rook M, Simpson P. A double-blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol. 1987; 2: 159-169.
  • 36
    Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomized placebo-controlled international study using the cognitive drug research computerized assessment system. Dement Geriatr Cogn Disord. 2002; 13: 183-192.
  • 37
    Cognitive Drug Research. Available at: http://www.cognitivedrugresearch.com/newcdr/ Accessed on June 28, 2008.
  • 38
    O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes KA. The cognitive and psychomotor effects of morphine in healthy subjects: a randomised controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain. 2000; 85: 209-215.
  • 39
    Walker MP, Ayre GA, Cumming, JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology. 2000; 54: 1616-1625.
  • 40
    Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA or ‘ecstasy’: evidence for memory deficits. J Psychopharmacol. 1998; 12: 79-83.
  • 41
    Walker LG, Wesne KA, Heys SD, Walker MB, Lolley J, Eremin O. The cognitive effects of recombinant Interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. Eur J Cancer. 1996; 32A: 2275-2283.
  • 42
    Keith MS, Stanislav SW, Wesnes KA. Validity of a cognitive computerized assessment system in brain-injured patients. Brain Inj. 1998; 12: 1037-1043.
  • 43
    Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry. 2000; 177: 252-256.
  • 44
    Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson's disease. Neurology. 2005; 65: 1654-1656.
  • 45
    Kennedy DO, Scholey AB, Wesnes KA. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng and a ginkgo/ginseng combination to healthy young adults. Physiol Behav. 2002; 75: 739-751.
  • 46
    Kennedy DO, Scholey AB, Wesnes KA. Dose dependent changes in cognitive performance and mood following acute administration of ginseng to healthy young volunteers. Nutr Neurosci. 2001; 4: 295-310.
  • 47
    Kennedy DO, Scholey AB, Wesnes, KA. Differential, dose dependent changes in cognitive performance following acute administration of a ginkgo biloba/panax ginseng combination to healthy young volunteers. Nutr Neurosci. 2001; 4: 399-412.
  • 48
    Wesnes K, Faleni RA, Hefting NR, et al. The cognitive, subjective and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints. Psychopharmacol Bull. 1997; 33: 677-683.
  • 49
    Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). 2000; 151: 416-423.
  • 50
    McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000; 356: 2031-2036.
  • 51
    Wesnes KA, Simpson PM, White L, et al. Cholinesterase inhibition in the scopolamine model of dementia. Ann N Y Acad Sci. 1991; 640: 268-227.
  • 52
    Kohli S, Griggs JJ, Roscoe JA, et al. Self-reported cognitive impairment in cancer patients. J Oncol Pract. 2007; 3: 5459.
  • 53
    Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006; 54: 925-931.
  • 54
    Layton J. Is science phasing out sleep? How Stuff Works. Available at: http://health.howstuffworks.com/sleep-is-so-last-year.htm. Accessed in May 2007.
  • 55
    Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine, methylphenidate and modafinil-induced wakefulness, evidenced by c-mos immunocytochemistry, in the cat. Proc Natl Acad Sci U S A. 1996; 92: 14128-14133.
  • 56
    Engber TM. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett. 1998; 24: 95-98.
  • 57
    Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med. 2000; 1: 231-243.
  • 58
    Luoma ML, Hakamies-Blomqvist L. The meaning of quality of life in patients being treated for advanced breast cancer: a qualitative study. Psychooncology. 2004; 13: 729-739.
  • 59
    Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research [review]. Semin Oncol. 2003; 30: 749-762.